Morningstar
•
Apr 30, 2026
GSK plc: GSK Earnings: Strong Start to the Year Due to Specialty Medicines and Shingrix
Summary
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology,
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Market Digest: AMP, EPD, FCX, FHI, LLY, RCL, WDC, WY, META, HCA
May 04, 2026
•
META, WY, AMP, FHI, WDC, HCA, EPD, LLY, FCX, RCL
Analyst Report: Eli Lilly & Co
May 04, 2026
•
LLY
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Bristol-Myers Squibb Company
Apr 30, 2026
•
BMY
